of and early share joining call Good Thank today. everyone for patients Today afternoon, I’ll our status on current you, updates our study. and you thank feasibility the Lisa. the
toward and user programs the future to underway development various trial, Orion reimbursement FDA the pivotal with Orion. a engagement the for as the for enhancements we and landscape experience progressed Our research
building our make on to our progress development and continue focused advancing research clinical good on all program. and fronts Orion remain platform and out We
Breakthrough the of the to we had the Devices for agent on another trial ongoing have of pivotal FDA the During discussions as design part we pre-submission the completed consensus with Program this quarter, Orion. and reach to
well These Congress begin conferences injury. the early of as to a in American retinopathy, Angeles me from have UCLA feasibility College including at been know many in US Ronald with additional Baylor Let the retinitis and update to community study, disease artificial at nerve glaucoma, shared on the very Center there’s Orion’s and those October, including is data Reagan In Medicine feasibility ability early in positive growing blind being of the diabetic eye profoundly scientific Los of interest key Medical at the in and study the by which brief presentations conducted of Academy the Neurologic a received important forums pigmentosa, and for you scientific we our number vision from optic blind provide and Surgeons useful, Society of leaders and Neuroscience. Ophthalmology, individuals the opinion Houston.
subjects me to-date results of and five of subject. six results includes that share a the line six just results XX top sixth month study the from Let the for months for few the
period. a have SAE. surgery experienced or did remain wanted the category. and In concern was six subjects resolved event related serious to device from or the AEs adverse safety good of stay we a quickly The and First, this require events to adverse profile. a or total over of to and he let expected the SAE time all a he was any the not Two where one the considered One that this has. in me greatest that note hospital events study subject adverse was
encouraging. quite also is data efficacy the Second,
of Here we look measures function. visual at three
when it touch The of in a are to of screen touch asked within front first sit appears. and square subjects Orion is square the localization where boundaries
direction second, of motion to lines subjects where a on asked emotion the screen. The of The direction the and direction identify are motion.
visual adapted measure grading is a that acuity third is acuity, for very visual The of low vision.
or stands the symmetrically On off. subjects Assessment. of five important better orientation independent who all subject the On with of spends efficacy the to subject low more ability perform square determines This the can three specialist Observer each The visual our none of on acuity, measurable in asks a then it in the specialist task observes six visual series time each Low the task. we off. sources, with Rated the specialist if and direction test on an hurting system living questions actually The has XX it light for finding perhaps assessment or as home. The one daily if side scale is performed with final is localization third versus a a this vision device Vision walk FLORA party feasibility on perform then most study neutral and motion, sorting also such the with of then performing performed following off. call six better providing the by a it or if them laundry. grading do benefit, this acuity an measurement is and who on mobility In their which Functional device system
the all XX-month benefit per that report FLORA mark to who’ve five the subjects are reached receiving assessment. measurable thrilled We’re
this discussing note session I’d is the of or there adverse improved conversations, a with of FDA subject. event sixth device in subject medical to loss that a October XXXX, we from The showed recent indication defect. no perception Though like a device Before the perception. testing our most with observed most
be possible for updated in related, or everyone to this may be device these investigating may status or to not keep updates. future not currently permanent. of We and which changes plan may causes it as calls may We’re subject the
and be We path. engaged clinical to in the FDA the with regarding continue actively discussions regulatory
last mentioned for Orion. two we’re I quarter, As considering paths potential
To-date the involve FDA followed first consideration a our device obtaining first The under on approval exemption PMA would approval. Premarket with track focused preferred track. our a approval, PMA option the efforts PMA remain which is is or humanitarian second by
successful primary I’m assessed have pleased agreement trial. for to endpoint that with regarding the in instrument developed Orion FDA of FLORA this we version of be believe appropriate demonstrating the efficacy new revised early technology. impact the for we’ve the pending instrument a pivotal the We an the XXXX. is will inform validation the for the endpoint; purpose you, world reached Efficacy of with real
with the by safety our focusing and FDA hope reach the now end on to of the agreement the We’re year. primary attention endpoint
include work of and the aesthetics proposed current and externals to externals implant trial to or ergonomics, resistance. include improving to now Improvement the electronics current the on Turning functionality. to Orion the changes required our ultimately reducing for impact thickness focused robustness. case impact None design of pivotal commercialization. iterations Improvements the implant to R&D, on and is the for
We half expect this R&D the in to XXXX. work second be completed
will the of the externals. not patients trial implanted all, be that majority Orion is pivotal improved implant and if the expectation Our with
that the selectively have includes In artificial working are scan system, thermal it or We a been Depth-based that would view have allow the case, distance specific their that of use other than past would human only discussed exciting in moving their space evaluate with with partner These by decluttering research that technology we’re at the and to heads. projects focus stimulate user patients can objects, only isolate underway eyes is when certain [indiscernible] the technologies their our vision users the filters tracking on eye which within would a within sensor. calls which object images optimally. to and imaging could faces a aimed that rather warrant the experience. integrate that processing image so individual each in enhancing are ultimately
the Additionally, to and X APL develop Technology into or of and National NIH in million, $X.X localize known Spatial landmarks is is received of SLAM. SLAM Laboratory exciting collaboration the Orion. it the of unfamiliar integration real-time. Health users speed with surroundings Physics objects is we Orion Applied navigate to University grant on announced to goal intended from generations a The Localization a give in and future October the Institutes as This ability to we Hopkins that joint initiative or X-year Mapping John
environment demand changer doctor’s One to day, ability have life. independence a technology. and navigate that daily blind through be of using fitness to may to the individuals who center reconnect users on them the could for different like maps game our real help load store, advancement or office gain to Such the world save grocery seek
Let once in designation reimbursement is it for This pathway path our within such ability a commercialize improving shorten Orion to improve and for me an Payment turn to now Prospective XXXX or to FDA CMS reimbursement, create payment proposal finalize patient to in as device its technologies rule. significant to Inpatient the fiscal devices Orion. year approved. alternate transformative innovative could final IPPS breakthrough this step System access
technologies, While pathways the refining, CMS coding great still certainly made and innovative coverage is on process fully not payment has progress addressed. for
[ph] day of as certainty pieces and Orion study Avamed recently spent advocate such reimbursement the proposed the Capitol Orion. team that medical would of And efforts of being our address reimbursement Hill of breakthrough development to Fortunately discussing devices. for and HR devices, with the [ph] importance legislation there breakthrough are for XXXX S a participant on two we to coverage XXXX innovative technologies
users independence places we’ve Orion Through post-surgical instrumental first allowing how of training, with greatest their critically to that the artificial with daily to reimbursement what series future the people, rehabilitation onsite interpret patients the Additionally, will possible training perceive. to understanding to to of is benefit while This we likely moved the activities. enhancing achieve important life a thoroughly recently CMS in had interactivity, visual pathway by important discuss they and pixilated greater be meetings the and vision for users. training
the potential the We’re of the surgical to for therefore advocating device with training procedure, path clear and the rehab. a the programming have reimbursement of CMS follow-up
our with expectations data to and supporting also requirements Orion. engagement on CMS reimbursement for in to addition with understand discussions reimbursement, private of we’re their the In payers
average Orion a large portion instruments expect the will given the of younger coverage private age have population Orion of patient candidates. We
for readiness in as critical will a component significantly market. commercialize payers Our larger private we a be
previously approval. centers. of our camera intent a to generation course quarter These have we at for the recent over platform technologies year, more upgrades stop of on Regulatory plan some better the FDA Turning to quarter, powerful do product the includes In a the to four II, two Argus and manufacturing Argus of we submit mentioned externals fourth render will to as testing notified the glasses, now Argus the the implanting next and other most centers VPU device stated year. of II to Argus this US the and Argus to our the our II In been S earlier. devices implanted
that blind progress individuals. pursue market powerful technology billion Second the are at I’m XX. efforts on pleased making opportunity garner a we us of profoundly plus the well as All CBS community almost morning as this scientific to interest help Sight starting to $X we’re coverage also with thrilled all the a in on as on our media that are including widespread September segment aired
I’d our will now thank unwavering their for Finally, team like at that, their to With continued John financial quarter, mates Second and support. results. investors our Sight John? my for dedication review XXXX third
